Avanir
The ASPECT study evaluates the investigational drug AVP-786 to treat agitation in adults with Alzheimer's disease. Participation is voluntary and at no cost to participants, taking place in 110 international centers for 20 weeks.
The ASPECT study evaluates the investigational drug AVP-786 to treat agitation in adults with Alzheimer's disease. Participation is voluntary and at no cost to participants, taking place in 110 international centers for 20 weeks.
